Use of Contrast-Enhanced Ultrasound with Sonazoid for Evaluating the Radiotherapy Efficacy for Hepatocellular Carcinoma

• Main Authors: Akihiro Funaoka, Kazushi Numata, Atsuya Takeda, Yusuke Saigusa, Yuichirou Tsurugai, Hiromi Nihonmatsu, Makoto Chuma, Hiroyuki Fukuda, Masahiro Okada, Masayuki Nakano, Shin Maeda
• Format: Article
• Language: English
• Published: MDPI AG 2021-03-01
• Series: Diagnostics
• Subjects: hepatocellular carcinoma; radiotherapy; contrast-enhanced ultrasound; sonazoid
• Online Access: https://www.mdpi.com/2075-4418/11/3/486

Radiotherapy is one of the available curative therapies for hepatocellular carcinoma (HCC). We investigate the use of contrast-enhanced ultrasound using Sonazoid (SCEUS) in evaluating the efficacy of radiotherapy for HCC. We enrolled 59 patients with 59 HCCs in this retrospective study. Tumor size and tumor vascularity were evaluated using SCEUS before and 1, 3, 7, 10, and 13 months after radiotherapy. The median follow-up period was 44.5 months (range: 16–82 months). Of the HCCs, 95% (56/59) had no local recurrence, while 5% (3/59) did. At 13 months after radiotherapy, in cases with no local recurrence, SCEUS showed a reduction in tumor vascularity in all cases, while tumor size reduction (>30% reduction, compared with pre-radiotherapy) was observed in 82.1% (46/56). In all three cases of local recurrence, vascularity and tumor size reduction were not observed during the follow-up period and residual HCCs were demonstrated pathologically. Compared with cases with local recurrence, tumor size reduction and reduction in tumor vascularity (<i>p</i> < 0.001) were significantly greater in cases with no local recurrence at 13 months after radiotherapy. SCEUS may be useful in evaluating radiotherapy efficacy for HCC.